A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group.

@article{Stoute1997APE,
  title={A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group.},
  author={Jos{\'e} A Stoute and Moncef Slaoui and Donald Gray Heppner and Patricia Marie Momin and Kent E. Kester and Pierre Michel Desmons and Bruce T. Wellde and Nathalie Garçon and U Krzych and Martine Marchand},
  journal={The New England journal of medicine},
  year={1997},
  volume={336 2},
  pages={
          86-91
        }
}
BACKGROUND The candidate vaccines against malaria are poorly immunogenic and thus have been ineffective in preventing infection. We developed a vaccine based on the circumsporozoite protein of Plasmodium falciparum that incorporates adjuvants selected to enhance the immune response. METHODS The antigen consists of a hybrid in which the circumsporozoite protein fused to hepatitis B surface antigen (HBsAg) is expressed together with unfused HBsAg. We evaluated three formulations of this antigen… Expand

Paper Mentions

Interventional Clinical Trial
This was a phase I double blind controlled vaccine trial, evaluating safety, tolerability and immunogenicity of mixtures of N, R and C LSP derived from the P. vivax CS protein… Expand
ConditionsMalaria, Vivax
InterventionDrug, Other
Identification of two new protective pre-erythrocytic malaria vaccine antigen candidates
TLDR
This work identifies two promising malaria vaccine antigen candidates and suggests that a multi-antigen vaccine may be more efficacious than a single antigen vaccine. Expand
The Synthetic Plasmodium falciparum Circumsporozoite Peptide PfCS102 as a Malaria Vaccine Candidate: A Randomized Controlled Phase I Trial
TLDR
PfCS102 peptide was safe and highly immunogenic, allowing the design of more advanced trials to test its potential for protection, and two or three immunizations with a dose of 30 µg formulated with AS02A appeared the most appropriate choice for such studies. Expand
Phase I Testing of a Malaria Vaccine Composed of Hepatitis B Virus Core Particles Expressing Plasmodium falciparum Circumsporozoite Epitopes
TLDR
These studies support ICC-1132 as a promising malaria vaccine candidate for further clinical testing using more-potent adjuvant formulations and confirm the potential of modified HBc virus-like particles as a delivery platform for vaccines against other human pathogens. Expand
Immunogenicity of Plasmodium falciparum circumsporozoite protein multiple antigen peptide vaccine formulated with different adjuvants.
TLDR
High degree of immunogenicity of MAP4(NANP)6P2P30 vaccine formulated in liposomes, lipid A and aluminum hydroxide provides the foundation for consideration of human trials with this formulation. Expand
Protective efficacy of the RTS,S/AS02 Plasmodium falciparum malaria vaccine is not strain specific.
RTS,S/AS02 is a recombinant protein malaria vaccine that contains a large portion of the C-terminal of the circumsporozoite protein (CSP) sequence of the NF54 isolate of Plasmodium falciparum fusedExpand
Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine
TLDR
There is a dose-dependent immunological threshold for establishing high-level protection against malaria that can be achieved with IV administration of a vaccine that is safe and meets regulatory standards. Expand
An epitope-based malaria vaccine targeting the junctional region of circumsporozoite protein
TLDR
It is demonstrated that a Qβ VLP-based vaccine targeting the CIS43 epitope combined with various adjuvants is highly immunogenic in mice and macaques, elicits long-lasting anti-CSP antibodies, and inhibits parasite infection in a mouse model. Expand
Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant.
TLDR
Two phase I vaccine trials were conducted to test the immunogenicity and safety of a vaccine containing three recombinant malaria antigens from the asexual stage of Plasmodium falciparum: MSP1, MSP2 and a portion of RESA and Montanide ISA720 adjuvant. Expand
The challenges of a circumsporozoite protein-based malaria vaccine
TLDR
It is highlighted how both structure-guided vaccine design and a better understanding of the immune response to PfCSP can inform a second generation of PfC SP-based vaccines stimulating a broader range of protective targets within PfCsp. Expand
A field trial to assess a blood-stage malaria vaccine.
TLDR
The malaria vaccine did not provide significant protection against clinical malaria, but on the basis of secondary results, it may have strain-specific efficacy. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 31 REFERENCES
Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine.
TLDR
Twenty malaria-naive volunteers received a recombinant Plasmodium falciparum malaria vaccine (RTS,S) containing 19 NANP repeats and the carboxy terminus of the circumsporozoite (CS) antigen coexpressed in yeast with hepatitis B surface antigen and MPL enhanced CS antibody levels. Expand
Safety, immunogenicity and limited efficacy study of a recombinant Plasmodium falciparum circumsporozoite vaccine in Thai soldiers.
TLDR
The R32Tox-A vaccine was found to be safe and to elicit antibody responses in all vaccinees, and secondary analyses revealed that CS antibody levels were lower in vaccinee malaria cases than in non-cases, 3 and 5 months after the third dose of vaccine. Expand
Phase I clinical trial of a recombinant malaria vaccine consisting of the circumsporozoite repeat region of Plasmodium falciparum coupled to hepatitis B surface antigen.
R16HBsAg is an experimental recombinant malaria vaccine consisting of 16 repeats of a four amino acid sequence (Asn-Ala-Asn-Pro or NANP) of the circumsporozoite (CS) protein of Plasmodium falciparumExpand
Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications.
TLDR
Unless immunization with sporozoite vaccines induces antibodies that are quantitatively or qualitatively superior to the circumsporozoite antibodies in these adults, it is unlikely that such antibodies will prevent infection in areas with as intense malaria transmission as western Kenya. Expand
SAFETY AND EFFICACY OF A RECOMBINANT DNA PLASMODIUM FALCIPARUM SPOROZOITE VACCINE
TLDR
This study confirms that human beings can be protected by CS protein subunit vaccines and provides a framework for the further development and testing of more immunogenic sporozoite vaccines. Expand
Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites
TLDR
This first synthetic peptide parenteral vaccine against a communicable disease tested in man is safe and stimulates biologically active antibodies, which encourage the development of improved vaccine formulations which, by enhancing immunogenicity, may lead to practical vaccines to assist in the control of falciparum malaria. Expand
Safety, immunogenicity, and efficacy of a malaria sporozoite vaccine administered with monophosphoryl lipid A, cell wall skeleton of mycobacteria, and squalane as adjuvant.
TLDR
Data are consistent with other studies, and indicate that vaccine-induced antibodies against the repeat region of PfCSP can prevent effective sporozoite infection of hepatocytes in humans. Expand
Safety and immunogenicity of a Plasmodium falciparum sporozoite vaccine: boosting of antibody response in a population with prior natural exposure to malaria.
TLDR
Responses to subunit sporozoite vaccine paralleled response to prior natural sporozoites exposure and was significant and prolonged in a population with prior natural exposure to malaria. Expand
Rationale for the development of an engineered sporozoite malaria vaccine.
TLDR
This chapter discusses the rationale for developing sporozoite vaccines, the infective stages of the parasite found in the salivary glands of female Anopheles mosquitoes, and its implications for malaria vaccine development. Expand
Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites.
TLDR
Analysis of the humoral and cellular immune responses of these protected volunteers is expected to yield important clues to additional targets of immunity against the pre-erythrocytic stages of malaria parasites. Expand
...
1
2
3
4
...